Work

A Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for Patients with CML in Cytogenetic Remission with Residual Disease Detectable by Q-PCR.

Year: 2009

Type: article

Source: Blood

DOI: 10.1182/blood.v114.22.2194.2194

Authors: Ravi Bhatia, David S. Snyder, Allen Lin, Jennifer Arceo, Linda Seymour, Michael Deininger, Jerald Radich, Suzette Blanchard, Stephen Forman

Institutions: City Of Hope National Medical Center, OHSU Knight Cancer Institute, Fred Hutch Cancer Center

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2546777028

FWCI: 0.792

Cites:

Cited by: 7

Related to: 10